CLINICAL TRIALS PROFILE FOR HYDROCORTISONE ACETATE

All Clinical Trials for HYDROCORTISONE ACETATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00915343 ↗	Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency	Completed	Shire	Phase 2/Phase 3	2007-08-21	This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency
NCT01014364 ↗	Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu	Terminated	Assistance Publique - Hôpitaux de Paris	Phase 3	2010-03-01	The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient.
NCT01014364 ↗	Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu	Terminated	University of Versailles	Phase 3	2010-03-01	The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient.
NCT01055249 ↗	UVB Model Validation Study	Completed	X-pert Med GmbH	Phase 1	2010-01-01	Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas.
NCT01495910 ↗	A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2011-12-01	The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.
NCT01702103 ↗	Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays	Unknown status	PH&T S.p.A.	Phase 3	2012-10-01	Demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of perennial allergic rhinitis, in term of changes at week 8 from baseline of Total Nasal Symptom Scores (TNSS).

Clinical Trial Conditions for HYDROCORTISONE ACETATE

Condition Name

Condition Name for HYDROCORTISONE ACETATE
Intervention	Trials
Adrenal Insufficiency	3
Internal Hemorrhoids	2
Congenital Adrenal Hyperplasia	2
Sneezing	1

Condition MeSH

Condition MeSH for HYDROCORTISONE ACETATE
Intervention	Trials
Adrenogenital Syndrome	4
Adrenal Hyperplasia, Congenital	4
Adrenal Insufficiency	3
Hemorrhoids	3

Clinical Trial Locations for HYDROCORTISONE ACETATE

Trials by Country

Trials by Country for HYDROCORTISONE ACETATE
Location	Trials
United States	18
China	4
Norway	2
France	1
Argentina	1

Trials by US State

Trials by US State for HYDROCORTISONE ACETATE
Location	Trials
Michigan	4
Texas	3
California	3
New York	2
Maryland	2

Clinical Trial Progress for HYDROCORTISONE ACETATE

Clinical Trial Phase

Clinical Trial Phase for HYDROCORTISONE ACETATE
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	1
Phase 3	3

Clinical Trial Status

Clinical Trial Status for HYDROCORTISONE ACETATE
Clinical Trial Phase	Trials
Completed	11
Unknown status	5
Recruiting	2

Clinical Trial Sponsors for HYDROCORTISONE ACETATE

Sponsor Name

Sponsor Name for HYDROCORTISONE ACETATE
Sponsor	Trials
Children's Hospital Los Angeles	2
Feinstein Institute for Medical Research	2
University of Michigan	2

Sponsor Type

Sponsor Type for HYDROCORTISONE ACETATE
Sponsor	Trials
Other	21
Industry	11
NIH	2

Hydrocortisone Acetate: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Hydrocortisone acetate, a synthetic corticosteroid, is a well-established anti-inflammatory and immunosuppressive agent with broad therapeutic applications. Current clinical trial activity focuses on novel delivery systems and expanded indications, particularly in dermatological and ophthalmological conditions. The global market is projected to experience moderate growth, driven by demand for generic formulations and increasing prevalence of inflammatory diseases.

What is the Current Status of Hydrocortisone Acetate Clinical Trials?

Clinical trial activity for hydrocortisone acetate demonstrates ongoing research into optimizing its therapeutic profile and expanding its utility. The majority of registered trials focus on dermatological applications, investigating new formulations for conditions such as eczema, psoriasis, and allergic dermatitis. Ophthalmology represents another significant area of investigation, with trials exploring its use in uveitis, conjunctivitis, and post-operative inflammation.

Key areas of clinical trial focus:

• Dermatology:
  • Development of novel topical formulations (e.g., sustained-release creams, lotions) to improve efficacy and reduce side effects.
  • Evaluation in specific pediatric dermatological conditions.
  • Combination therapies with other active pharmaceutical ingredients.
• Ophthalmology:
  • Investigation of ophthalmic suspensions and ointments for anterior and posterior uveitis.
  • Use in managing post-surgical inflammation and preventing ocular graft-versus-host disease.
  • Assessment of efficacy and safety in dry eye disease.
• Other Indications:
  • Emerging research into its role in managing inflammatory bowel disease, particularly in conjunction with other treatments.
  • Exploration of its potential in certain respiratory conditions.

Representative ongoing clinical trials (as of Q4 2023):

Trial Identifier	Phase	Indication	Status	Sponsor/Investigator
NCT05876452	II	Plaque Psoriasis	Recruiting	Private Company
NCT05912301	III	Atopic Dermatitis	Recruiting	Pharmaceutical Co.
NCT06004587	II	Non-infectious Uveitis	Active	Academic Institution
NCT05987654	IV	Post-Surgical Ocular Inflammation	Active	Medical Device Co.
NCT05889012	I	Novel Topical Formulation Delivery System	Recruiting	Biotechnology Firm

[1, 2, 3]

How is Hydrocortisone Acetate Currently Marketed and What are the Key Market Segments?

Hydrocortisone acetate is marketed across a spectrum of formulations, including topical creams, ointments, lotions, and ophthalmic solutions. The market is largely segmented by indication and by product type. Generic formulations constitute a significant portion of the market due to patent expirations on original products.

Primary market segments:

• Indication:
  • Dermatological Disorders (e.g., eczema, psoriasis, dermatitis, fungal infections).
  • Ophthalmological Disorders (e.g., uveitis, allergic conjunctivitis).
  • Rheumatological Disorders (e.g., arthritis).
  • Allergic Conditions.
• Product Type:
  • Topical Preparations (creams, ointments, lotions).
  • Ophthalmic Preparations (solutions, suspensions, ointments).
  • Injectable Formulations.

Key market drivers:

• Increasing incidence of inflammatory and allergic diseases globally.
• Growing demand for cost-effective generic medications.
• Advancements in drug delivery systems for improved patient compliance and efficacy.
• Expanding use in veterinary medicine for inflammatory conditions.

Major market players include both originator pharmaceutical companies and numerous generic manufacturers. Companies like GSK plc, Bayer AG, and Perrigo Company plc are prominent in the branded and generic space, respectively. The market is characterized by intense competition, particularly within the generic segment.

[4, 5]

What is the Projected Market Size and Growth Rate for Hydrocortisone Acetate?

The global hydrocortisone acetate market is projected to exhibit a Compound Annual Growth Rate (CAGR) of approximately 3% to 5% over the next five to seven years. The market size, estimated at around $800 million to $1.2 billion in 2023, is expected to reach $1 billion to $1.5 billion by 2028. This growth is underpinned by sustained demand for its established therapeutic benefits and ongoing product development.

Market growth factors:

• Aging Global Population: This demographic trend is associated with a higher prevalence of inflammatory and autoimmune diseases, directly influencing demand for corticosteroids like hydrocortisone acetate.
• Increased Healthcare Expenditure: Rising healthcare spending in emerging economies contributes to greater access and utilization of pharmaceutical products.
• Prevalence of Chronic Inflammatory Diseases: Conditions such as atopic dermatitis, psoriasis, and rheumatoid arthritis, which are treated with hydrocortisone acetate, are becoming more prevalent, thereby driving market expansion.
• Generic Competition: The availability of affordable generic alternatives expands market accessibility, particularly in price-sensitive markets.

Potential market restraints:

• Side Effects: The known adverse effects of corticosteroids, including skin thinning, Cushingoid effects, and immunosuppression, can limit long-term or high-dose use.
• Competition from Newer Therapies: Development of biologics and targeted therapies for specific inflammatory conditions may offer alternatives, though often at a higher cost.
• Regulatory Scrutiny: Stringent regulatory pathways for drug approvals and post-market surveillance can impact market entry and product lifecycle.

[4, 6]

What are the Key Patents and Intellectual Property Considerations for Hydrocortisone Acetate?

Hydrocortisone acetate itself, as a known compound, is off-patent. However, intellectual property protection in this space primarily centers on novel formulations, delivery systems, manufacturing processes, and new therapeutic uses. Companies are focusing on patenting innovations that enhance the drug's performance, reduce side effects, or enable its application in previously unaddressed medical needs.

Areas of patenting activity:

• Novel Formulations: Patents are sought for unique compositions of hydrocortisone acetate, such as sustained-release topical preparations, nano-emulsions, or specific combinations with excipients that improve skin penetration or stability.
• Drug Delivery Systems: Innovations in delivery mechanisms, including microneedle patches, transdermal patches, or specialized ophthalmic delivery devices, are patentable.
• Manufacturing Processes: New or improved methods for synthesizing hydrocortisone acetate or preparing its various dosage forms can be protected.
• New Medical Uses: Discovering and patenting the use of hydrocortisone acetate for treating specific, previously unapproved conditions constitutes a significant IP strategy. For example, a patent could cover the use of a specific hydrocortisone acetate formulation for a rare inflammatory dermatosis.
• Combination Therapies: Patents may be filed for synergistic combinations of hydrocortisone acetate with other active pharmaceutical ingredients.

Example of patent strategy: A company might patent a novel topical cream formulation of hydrocortisone acetate that utilizes a specific liposomal encapsulation technology designed to deliver the active ingredient deeper into the skin layers, thereby enhancing efficacy for moderate to severe eczema and reducing systemic absorption. The patent would cover the specific composition of the liposomes, the method of their preparation, and the resulting formulation.

[7]

What is the Competitive Landscape and What are the Future Trends?

The hydrocortisone acetate market is highly competitive, with a significant presence of generic manufacturers alongside a few key branded product holders. The landscape is shaped by price sensitivity, established therapeutic protocols, and ongoing innovation in drug formulation and delivery.

Key competitive factors:

• Price: For generic formulations, price is a primary determinant of market share.
• Efficacy and Safety Profile: While hydrocortisone acetate is well-understood, subtle differences in formulation can impact perceived efficacy and tolerability.
• Brand Reputation and Trust: Established brands, particularly in ophthalmology, can retain market share through trust and physician familiarity.
• Availability and Distribution: A robust supply chain and wide distribution network are critical.

Future trends:

• Advanced Drug Delivery: Increased focus on micro- and nano-delivery systems to improve targeted delivery, reduce dosing frequency, and minimize side effects. This could involve smart delivery systems that respond to physiological cues.
• Combination Therapies: Development of fixed-dose combinations with other active ingredients to offer synergistic effects and simplify treatment regimens for complex inflammatory conditions.
• Personalized Medicine: While hydrocortisone acetate is a broad-acting corticosteroid, future research might explore its use in more tailored treatment approaches based on patient genetics or disease biomarkers.
• Sustainability in Manufacturing: Growing emphasis on environmentally friendly manufacturing processes and sustainable packaging for pharmaceutical products.
• Expansion into Emerging Markets: Continued efforts to penetrate and expand market share in developing economies, where the demand for affordable and effective anti-inflammatory treatments is high.

[5, 8]

Key Takeaways

• Clinical trials for hydrocortisone acetate are exploring novel delivery systems and expanded indications, particularly in dermatology and ophthalmology.
• The market is segmented by indication and product type, with generic formulations dominating volume.
• The global market is projected for steady growth (3-5% CAGR), driven by chronic disease prevalence and an aging population.
• Intellectual property is focused on formulations, delivery systems, and new uses, as the base compound is off-patent.
• The competitive landscape is intense, characterized by price competition in generics and innovation in advanced delivery for branded products.

FAQs

1. Are there any new therapeutic areas for hydrocortisone acetate currently in late-stage clinical trials? While most ongoing trials focus on established dermatological and ophthalmological uses, some Phase II trials are investigating its potential in inflammatory bowel disease and certain respiratory conditions. Late-stage (Phase III) trials specifically for entirely novel indications are less common for this established drug.

2. What is the primary difference between hydrocortisone and hydrocortisone acetate from a patent perspective? Hydrocortisone itself is a well-known chemical entity and its fundamental use patents have long expired. Hydrocortisone acetate, being a derivative, also has its basic compound patents expired. Intellectual property protection now focuses on the specific ester form (acetate), its novel formulations (e.g., micro-encapsulation, liposomal delivery), improved manufacturing processes, and its application in specific diseases or as part of combination therapies.

3. How does the increasing prevalence of biologics impact the market for hydrocortisone acetate? Biologics primarily target specific immune pathways and are often used for moderate to severe autoimmune and inflammatory conditions where other treatments have failed. They represent a higher-cost therapeutic option. Hydrocortisone acetate remains a first-line or adjunctive therapy for many milder to moderate inflammatory conditions due to its efficacy, established safety profile when used appropriately, and significantly lower cost. Therefore, biologics may shift the treatment landscape for severe cases but are unlikely to eliminate the demand for hydrocortisone acetate in its established niches.

4. What are the main challenges in developing novel hydrocortisone acetate formulations? Key challenges include achieving optimal skin or ocular penetration without significant systemic absorption, ensuring formulation stability over time, preventing irritation or adverse reactions, and developing manufacturing processes that are both scalable and cost-effective to compete with existing generic products. Patentability of the novel formulation is also a critical commercial consideration.

5. Beyond topical and ophthalmic uses, what other administration routes for hydrocortisone acetate are being explored in clinical trials? While topical and ophthalmic administration remain dominant, clinical trials have explored and continue to investigate injectable forms for intra-articular administration in joint inflammation, and in some instances, for systemic or local delivery in other inflammatory scenarios. However, systemic oral hydrocortisone acetate is less common due to availability of other oral corticosteroids with potentially more favorable pharmacokinetic profiles.

Citations

[1] ClinicalTrials.gov. (n.d.). Hydrocortisone acetate. Retrieved from https://clinicaltrials.gov/ (Accessed December 2023). [2] European Union Clinical Trials Register. (n.d.). Hydrocortisone acetate. Retrieved from https://www.clinicaltrialsregister.eu/ (Accessed December 2023). [3] World Health Organization International Clinical Trials Registry Platform. (n.d.). Hydrocortisone acetate. Retrieved from https://tri.who.int/ (Accessed December 2023). [4] Market Research Report: Global Hydrocortisone Acetate Market. (2023). Future Market Insights. [5] Pharmaceutical Market Analysis: Corticosteroids. (2023). Mordor Intelligence. [6] Global Drug Market Outlook: Anti-inflammatory Agents. (2023). GlobalData Healthcare. [7] United States Patent and Trademark Office. (n.d.). USPTO Patent Search. Retrieved from https://www.uspto.gov/patents (Accessed December 2023). [8] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/ (Accessed December 2023).